Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy
Open Access
- 20 May 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 8 (6) , 692-704
Abstract
Cancer immunotherapy is a powerful treatment strategy that mobilizes the immune system to fight disease. Cancer vaccination is one form of cancer immunotherapy, where spatiotemporal control of the delivery of tumor-specific antigens, adjuvants, and/or cytokines has been key to successfully activating the immune system. Nanoscale materials that take advantage of chemistry to control the nanoscale structural arrangement, composition, and release of immunostimulatory components have shown significant promise in this regard. In this Outlook, we examine how the nanoscale structure, chemistry, and composition of immunostimulatory compounds can be modulated to maximize immune response and mitigate off-target effects, focusing on spherical nucleic acids as a model system. Furthermore, we emphasize how chemistry and materials science are driving the rational design and development of next-generation cancer vaccines. Finally, we identify gaps in the field that should be addressed moving forward and outline future directions to galvanize researchers from multiple disciplines to help realize the full potential of this form of cancer immunotherapy through chemistry and rational vaccinology.Keywords
Funding Information
- American Cancer Society (PF-20-046-01 - LIB)
- American Committee for the Weizmann Institute of Science
- National Institutes of Health (P50CA221747, R01CA208783)
- Alexander S. Onassis Public Benefit Foundation
- Polsky Urologic Cancer Institute
This publication has 136 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- In vivo modulation of dendritic cells by engineered materials: Towards new cancer vaccinesNano Today, 2011
- Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responsesNature Materials, 2011
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Whole tumor antigen vaccinesSeminars in Immunology, 2010
- A self-assembling peptide acting as an immune adjuvantProceedings of the National Academy of Sciences, 2009
- Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccinesProceedings of the National Academy of Sciences, 2008
- Double-stranded RNA- and CpG DNA-induced immune responses in Atlantic salmon: Comparison and synergiesVaccine, 2008
- Mass Spectrometry of Self-Assembled Monolayers: A New Tool for Molecular Surface ScienceACS Nano, 2008
- Robust immune responses elicited by a fully synthetic three-component vaccineNature Chemical Biology, 2007